Dissolution enhancement of felodipine by amorphous nanodispersions using an amphiphilic polymer: insight into the role of drug–polymer interactions on drug dissolution

References

• Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47–60
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersion as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068–1075
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Drug-like properties and the cause of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235–249
   PubMed Web of Science ®Google Scholar
• Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water- soluble drugs. Int J Pharm 2004;284:109–122
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Poor aqueous solubility – an industry wide problem in drug discovery. Am Pharm Rev 2002;5:82–85
   Google Scholar
• Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J Control Release 2010;141:300–302
   PubMed Web of Science ®Google Scholar
• Yalkowsky SH. Techniques of solubilization of drugs. New York: Marcel Dekker; 1981
   Google Scholar
• Mooter GV. The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate. Drug Discov Today 2012;9:e79–e85
   Google Scholar
• Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002;231:131–144
   PubMed Web of Science ®Google Scholar
• Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 1961;9:866–872
   Web of Science ®Google Scholar
• Vo CLN, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm 2013;85:799–813
   PubMed Web of Science ®Google Scholar
• Gao P. Amorphous pharmaceutical solids: characterization, stabilization, and development of marketable formulations of poorly soluble drugs with improved oral absorption. Mol Pharm 2008;5:903–904
   PubMed Web of Science ®Google Scholar
• Saltiel E, Ellrodt AG, Monk JP, Langley MS. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1988;36:387–428
   PubMed Web of Science ®Google Scholar
• Ekelund LG, Ulvenstam G, Walldius G, Aberg A. Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris. Am J Cardiol 1994;73:658–660
   PubMed Web of Science ®Google Scholar
• USP, 37/NF 32 General Notices and requirements. 2014
   Google Scholar
• Edgar B, Lundborg P, Regardh CG. Clinical pharmacokinetics of felodipine – a summary. Drugs 1987;34:16–27
   PubMed Web of Science ®Google Scholar
• Meher JG, Tarai M, Yadav NP, et al. Development and characterization of cellulose–polymethacrylate mucoadhesive film for buccal delivery of carvedilol. Carbohydr Polym 2013;96:172–180
   PubMed Web of Science ®Google Scholar
• Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery – a promising option for orally less efficient drugs. J Control Release 2006;114:15–40
   PubMed Web of Science ®Google Scholar
• Rumondor ACF, Stanford LA, Taylor LS. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res 2009;26:2599–2606
   PubMed Web of Science ®Google Scholar
• Rumondor ACF, Ivanisevic I, Bates S, et al. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm Res 2009;26:2523–2534
   PubMed Web of Science ®Google Scholar
• Karavas E, Georgarakis E, Bikiaris D, et al. Hydrophilic matrices as carriers in felodipine solid dispersion system. Prog Colloid Polym Sci 2001;118:149–152
   Google Scholar
• Karavas E, Georgarakis E, Sigalas MP, et al. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug–polymer interactions. Eur J Pharm Biopharm 2007;66:334–347
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631–644
   PubMed Web of Science ®Google Scholar
• Hardung H, Djuric D, Ali S. Combining HME and solubilization: soluplus®-the solid solution. Drug Deliv Tech 2010;10:20–27
   Google Scholar
• Reintjes T. Solubility enhancement with BASF Pharma polymers solubilizer compendium. Germany: BASF SE; 2011
   Google Scholar
• Ali S, Langley N, Djuric D, Kolter K. Eyes on excipients. Available from: http://www.pharma-ingredients.basf.com/Documents/ENP/Articles/EN/EyeOnExcipients_1010TC.pdf [last accessed 23 Mar 2014]
   Google Scholar
• Ruchatz F, Kleinebudde P, Muller BW. Residual solvents in biodegradable microparticles. Influence of process parameters on the residual solvent in microparticles produced by the aerosol solvent extraction system (ASES) process. J Pharm Sci 1997;86:101–105
   PubMed Web of Science ®Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Impurities: Guideline for residual solvents. Q3C (R5). 2011
   Google Scholar
• Karavas E, Ktistis G, Xenakis A, Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur J Pharm Biopharm 2006;63:103–114
   PubMed Web of Science ®Google Scholar
• Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecular dispersed amorphous felodipine. J Pharm Sci 2006;95:2692–2705
   PubMed Web of Science ®Google Scholar
• Mooter GV, Wuyts M, Blaton N, et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 2001;12:261–269
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Hancock BC, Zografi G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci 1995;84:983–986
   PubMed Web of Science ®Google Scholar
• Shamma RN, Basha M. Soluplus®: a novel polymeric solubilizer for optimization of carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol 2013;237:406–414
   Web of Science ®Google Scholar
• Taupitz T, Dressman JB, Klein S. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. Eur J Pharm Biopharm 2013;84:208–218
   PubMed Web of Science ®Google Scholar
• Higuchi T, Connors KA. Phase-solubility techniques. In: Reilley CN, ed. Advances in analytical chemistry and instrumentation. Vol. 4. New York: Wiley-Interscience; 1965:117–212
   Google Scholar
• Patel VF, Liu F, Brown MB. Modeling the oral cavity: in vitro and in vivo evaluations of buccal drug delivery systems. J Control Release 2012;161:746–756
   PubMed Web of Science ®Google Scholar
• Jaipal A, Pandey MM, Abhishek A, et al. Interaction of calcium sulfate with xanthan gum: effect on in vitro bioadhesion and drug release behavior from xanthan gum based buccal discs of buspirone. Colloids Surf B 2013;111C:644–650
   Web of Science ®Google Scholar
• Collins AE, Deasy PB. Bioadhesive lozenge for the improved delivery of cetylpyridinium chloride. J Pharm Sci 1990;79:116–119
   PubMed Web of Science ®Google Scholar
• Han RY, Fang JY, Sung KC, Hu OYP. Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance. Int J Pharm 1999;177:201–209
   PubMed Web of Science ®Google Scholar
• Charde S, Mudgal M, Kumar L, Saha RN. Development and evaluation of buccoadhesive controlled release tablets of lercanidipine. AAPS PharmSciTech 2008;9:182–190
   PubMed Web of Science ®Google Scholar
• Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol 1975;27:48–49
   PubMed Web of Science ®Google Scholar
• Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol 1996;20:64–74
   Google Scholar
• Weuts I, Kempen D, Decorte A, et al. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. Eur J Pharm Sci 2005;25:313–320
   PubMed Web of Science ®Google Scholar
• Tang XC, Pikal MJ, Taylor LS. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res 2002;19:477–483
   PubMed Web of Science ®Google Scholar
• Lin-Vien D, Colthup NB, Fateley WG, Grasselli JG. The handbook of infrared and Raman characteristic frequencies of organic molecules. San Diego: Academic Press; 1991
   Google Scholar
• Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008;3:295–309
   PubMed Web of Science ®Google Scholar
• Brunner E. Reaktionsgeschwindigkeit in heterogenenSystemen. Z Phys Chem 1904;43:56–102
   Google Scholar
• Nernst W. Theorie der Reaktionsgeschwindigkeit in heterogenenSystemen. Z Phys Chem 1904;47:52–55
   Google Scholar
• Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989;51:9–17
   Web of Science ®Google Scholar